Author

Charlotte Lynne Bevan

Imperial College LondonORCID 0000-0002-7533-0552Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Molecular Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Organism:human· 3 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:protein structure prediction· 1

Frequent Co-Authors

Damien A. LeachiD· 2 shared Kyle K. GreenlandiD· 2 shared Alastair D.G. LambiD· 1 shared Alice Ormrod· 1 shared Anabel Varela‐Carver· 1 shared Aristotelis A. ChatziioannouiD· 1 shared Ash K. BahliD· 1 shared Chun‐Fui LaiiD· 1 shared

Activity by Year

2023-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Damien A. LeachORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Chromatin signalling pathways and FANCE amplification affect ATR inhibitor sensitivity in metastatic breast cancer

Jogitha Selvarajah, Rayzel Candida Fernandes, Marc P. Lorentzen, Emma Pei, Kyle K. Greenland, Zuza Kozik, Jyoti Sharma Choudhary, Charlotte Lynne Bevan

bioRxiv · Aug 26, 2025 · PreprintCancer Biology

IRE1 activity regulates tumour and microenvironment cell lineage states while stratifying localised and metastatic prostate cancer.

Dimitrios Doultsinos, Ingrid Tomljanović, Eleftherios D. Pilalis, Sophia M. Abusamra, Romuald Parmentier, I.E. Bridges, Sandy Figiel, Yanis Zekri, Joanna Hester, Damien A. Leach, Charlotte Lynne Bevan, Alastair D.G. Lamb, Wilbert T. Zwart, Aristotelis A. Chatziioannou, Clémentine Le Magnen, Ian Geoffrey Mills

This paper identifies IRE1 activity as a regulator of prostate cancer cell lineage states and shows its role in predicting prognosis and treatment response across localized and metastatic disease.

bioRxiv · Mar 13, 2025 · PreprintCancer Biology

The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer

Theodora A. Constantin, Anabel Varela‐Carver, Kyle K. Greenland, Gilberto Serrano de Almeida, Ellen Olden, Lucy Penfold, Simon Ang, Alice Ormrod, Damien A. Leach, Chun‐Fui Lai, Edward Ainscow, Ash K. Bahl, David Carling, Matthew John Fuchter, Simak Ali, Charlotte Lynne Bevan

This study investigates the antitumour activity of CT7001, a CDK7 inhibitor, in castration-resistant prostate cancer models, showing it inhibits proliferation and enhances enzalutamide efficacy.

British Journal of Cancer · Apr 19, 2023Peer-reviewedMolecular Biology